Ablynx aims to launch llama-based arthritis drug in 2013

01/26/2010 | Reuters

Ablynx CEO Edwin Moses said the Belgian company expects to launch its first llama-derived nanomedicine as early as 2013 through a partnership with Pfizer. The drug, which was developed from extra-small antibodies from llamas, could replace Pfizer's Enbrel as a blockbuster treatment for rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC